"We must make the most of Alzheimer's disease research," say two UK professors

24 August 2016
alzheimer-s-big

The focus of research has shifted significantly away from established and moderately severe Alzheimer’s disease to the much earlier stages of the illness and in some cases when symptoms are very mild or even absent. People have called this “Prodromal” Alzheimer’s disease or “Asymptomatic” Alzheimer’s disease.

This is the view of Alistair Burns, Professor of Old Age Psychiatry and Vice Dean for the Faculty of Medical and Human Sciences at The University of Manchester, and Prof Martin Rossor, the NIHR National Director for Dementia Research, Director of the NIHR Queen Square Dementia Biomedical Research Unit and a NIHR Senior Investigator which was posted as a blog on NHS England’s website today. It is important to plan for the future but there is some thinking and planning to be done before we arrive there, they said.

The Blog continues: For technocrats like us, of course, dementia is defined as a clinical syndrome and by definition has to have symptoms. So one would not talk about pre-symptomatic dementia (that would include everybody who did not have dementia, a bit like the club of which we are members, ie, people who have not yet won the Nobel Prize for medicine). As Alzheimer’s disease is largely defined in terms of the brain deposition of amyloid plaques and abnormal tangles of nerve fibers (due to the deposition of tau protein), you can certainly have these in the absence of symptoms.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical